SIGA Technologies Inc. (SIGA) August 06, 2012 4:30 pm ET Executives Todd Fromer - Managing Partner Eric A. Rose - Executive Chairman, Chief Executive Officer and Member of National Biodefense Science Board Daniel J. Luckshire - Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Secretary Analysts Adnan S. Butt - RBC Capital Markets, LLC, Research Division Joaquin Philip Horton Presentation Operator
Regarding our business operations, in particular, ST-246 and the BARDA contract, I want to highlight a few areas of progress. First, the labeling plan for ST-246 has been submitted and is being reviewed by the FDA. We are eligible for $12 million milestone payment from BARDA once the labeling plan is approved by the government. With respect to the delivery schedule for ST-246, we continue to expect to begin delivering the drug into the Strategic National Stockpile by the end of the first quarter 2013, and we also continue to expect to deliver the full 2 million courses under the contract within 24 months of the date of initial delivery.As mentioned on previous calls, the size and exact timing of each delivery will be determined in the future based on a variety of factors. Once we meet the 500,000 course delivery threshold, as noted in the contract, we'll be able to invoice BARDA for timely payment of all amounts then due. When we deliver courses of ST-246 into the SNS under the current procurement contract, our plan is that the courses will have a daily dosage of 600 milligrams over a 14-day regimen. We have set daily dosage at 600 milligrams per day after discussions with BARDA, the FDA and CDC. While our discussions have included the FDA, the 600-milligram dosage does not represent an FDA-regulatory decision on dosages at this time. It is our understanding that the FDA will express its formal regulatory decision on dosage after an NDA has been filed for ST-246, consistent with the timing and process once these -- with other drug candidate. Shifting gears, let me spend a minute discussing the progress we've made on the intravenous formulation, the IV formulation, of ST-246. As you will recall, in addition to an oral formulation, we are pursuing an IV formulation for the drug. This effort has been steadily progressing, and we continue to target an IND filing for the IV formulation by the fourth quarter of this year, and it may happen in the third quarter. Work on the IV formulation is important because it seeks to address an unmet need of a vulnerable segment of the population.
This concludes our prepared remarks. Thank you for attending this business update, and we'll now open the line for questions.Question-and-Answer Session Operator [Operator Instructions] The first question is from Adnan Butt of RBC Capital Markets. Adnan S. Butt - RBC Capital Markets, LLC, Research Division The first question is on the dosing. So you said for delivery, the assumption is 600 mg over a 14-day course. What could impact of the FDA's decision on dosing? And when you file the NDA first, when do you think you might file it? And secondly, what kind of dosing would you be looking for? Read the rest of this transcript for free on seekingalpha.com